Announcement on Subsidiary Receiving Tanzania Registration Certificate for Bivalent HPV Vaccine

Walvax Biotechnology Co., Ltd.·July 23, 2026·2 pages

✨ AI Summary

Yunnan Watson Biotech's subsidiary, Yuxi Zerun, has received a drug registration certificate from Tanzania for its bivalent HPV vaccine. This approval allows the vaccine to be marketed in Tanzania, a country with a high burden of cervical cancer. The company views this as a key achievement for its international strategy and plans to proceed with sales, though market timing and outcomes remain uncertain.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 300142 Stock Abbreviation: Watson Bio Announcement No.: 2026-059

Yunnan Watson Biotech Co., Ltd.

Announcement on Subsidiary Receiving Tanzania Registration Certificate for Bivalent HPV Vaccine

The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and are not aware of any false representations, misleading statements, or material omissions.

Yunnan Watson Biotech Co., Ltd. (hereinafter referred to as the "Company") subsidiary Yuxi Zerun Biotech Co., Ltd. (hereinafter referred to as "Yuxi Zerun") has recently received a drug registration certificate from the Tanzania Medicines and Medical Devices Authority for its bivalent human papillomavirus vaccine (Pichia pastoris) (trade name "WALRINVAX", hereinafter r

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.